VGLL4 inhibits EMT in part through suppressing Wnt/β-catenin signaling pathway in gastric cancer

Medical Oncology

Volumn 32, Issue 3, 2015, Pages

  Li, Hui ^a   Wang, Ziwei ^a   Zhang, Wei ^a   Qian, Kun ^a   Liao, Gang ^a   Xu, Wei ^a   Zhang, Shouru ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

EMT; Gastric cancer; Tumor progression; VGLL4; Wnt catenin

Indexed keywords

BETA CATENIN; MEMBRANE PROTEIN; UNCLASSIFIED DRUG; VESTIGIAL LIKE PROTEIN 4; WNT PROTEIN; CTNNB1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; VGLL4 PROTEIN, HUMAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER TISSUE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR XENOGRAFT; AGED; ANIMAL; BAGG ALBINO MOUSE; CASE CONTROL STUDY; CELL MOTION; DRUG SCREENING; GENETICS; METABOLISM; MORTALITY; PATHOLOGY; REFERENCE VALUE; STOMACH TUMOR; TUMOR CELL LINE; WNT SIGNALING PATHWAY;

AGED; ANIMALS; APOPTOSIS; BETA CATENIN; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MALE; MICE, INBRED BALB C; MIDDLE AGED; REFERENCE VALUES; STOMACH NEOPLASMS; TRANSCRIPTION FACTORS; WNT SIGNALING PATHWAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84923327725     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-015-0539-5     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.
2. Wu Y, Zhou BP. New insights of epithelial–mesenchymal transition in cancer metastasis. Acta Biochim Biophys Sin. 2008;40:643–50.
3. Fuxe J, Vincent T, de Herreros AG. Transcriptional crosstalk between TGF-beta and stem cell pathways in tumor cell invasion: role of EMT promoting Smad complexes. Cell Cycle. 2010;9:2363–74.
4. Bates RC, Mercurio AM. The epithelial–mesenchymal transition (EMT) and colorectal cancer progression. Cancer Biol Ther. 2005;4:365–70.
5. Thiery JP. Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442–54.
6. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelialmesenchymal transitions in development and disease. Cell. 2009;139:871–90.
7. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7:131–42.
8. Yang J, Weinberg RA. Epithelial–mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14:818–29.
9. Chen J, Wang T, Zhou Y-C, et al. Aquaporin 3 promotes epithelial-mesenchymal transition in gastric cancer. J Exp Clin Cancer Res. 2014;33:38.
10. Shi Min, Zheng Dayong, Sun Li, et al. XB130 promotes proliferation and invasion of gastric cancer cells. J Transl Med. 2014;12:1.
11. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9(4):265–73.
12. Bardeesy N, Cheng KH, Berger JH, Chu GC, et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev. 2006;20(22):3130–46.
13. Wang Z, Li Y, Kong D, Banerjee S, et al. Acquisition of epithelial–mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009;69(6):2400–7.
14. Fu Y, Zheng S, An N, et al. β-catenin as a potential key target for tumor suppression. Int J Cancer. 2011;129(7):1541–51.
15. Valenta T, Hausmann G, Basler K. The many faces and functions of β-catenin. EMBO J. 2012;31(12):2714–36.
16. Anson M, Crain-Denoyelle AM, Baud V, et al. Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. J Clin Invest. 2012;122(2):586–99.
17. Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev. 1997;11(24):3286–305.
18. Mao Y, Xu J, Li Z, et al. The role of nuclear β-catenin accumulation in the Twist2-induced ovarian cancer EMT. PLoS ONE. 2013;8(11):e78200.
19. Chen HH, Mullett SJ, Stewart AF. Vgl-4, a novel member of the vestigial-like family of transcription cofactors, regulates alpha1- adrenergic activation of gene expression in cardiac myocytes. J Biol Chem. 2004;279(29):30800–6.
20. Mielcarek M, Gunther S, Kruger M, et al. VITO-1, a novel vestigial related protein is predominantly expressed in the skeletal muscle lineage. Gene Expr Patterns. 2002;2(3–4):305–10.
21. Mielcarek M, Piotrowska I, Schneider A, et al. VITO-2, a new SID domain protein, is expressed in the myogenic lineage during early mouse embryonic development. Gene Expr Patterns. 2009;9(3):129–37.
22. Pobbati AV, Hong W. Emerging roles of TEAD transcription factors and its coactivators in cancers. Cancer Biol Ther. 2012;14(5):390–8.
23. Pobbati AV, Chan SW, Lee I, et al. Structural and functional similarity between the Vgll1-TEAD and the YAP-TEAD complexes. Structure. 2012;20(7):1135–40.
24. Richardson AL, Wang ZC, De Nicolo A, et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell. 2006;9(2):121–32.
25. Helias-Rodzewicz Z, Perot G, Chibon F, et al. YAP1 and VGLL3, encoding two cofactors of TEAD transcription factors, are amplified and overexpressed in a subset of soft tissue sarcomas. Genes Chromosom Cancer. 2012;49(12):1161–71.
26. Mann KM, Ward JM, Yew CC, et al. Sleeping beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci USA. 2012;109(16):5934–41.
27. Jin HS, Park HS, Shin JH, et al. A novel inhibitor of apoptosis protein (IAP)-interacting protein, Vestigial-like (Vgl)-4, counteracts apoptosis-inhibitory function of IAPs by nuclear sequestration. Biochem Biophys Res Commun. 2012;412(3):454–9.
28. Jiao S, Wang H, Shi Z, et al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell. 2014;25(2):166–80.
29. Xu MZ, Yao TJ, Lee NP, et al. Yes-associated protein is an independent prognostic marker in Hepatocellular carcinoma. Cancer. 2009;115:4576–85.
30. Xu W, Wang Z, Zhang W et al. Mutated K-ras activates CDK8 to stimulate the epithelial-to-mesenchymal transition in pancreatic cancer in part via the Wnt/β-catenin signaling pathway. Cancer Lett. 2015;356(2 Pt B):613–27.
31. Zha L, Zhang J, Tang W, et al. HMGA2 elicits EMT by activating the Wnt/b-catenin pathway in gastric cancer. Dig Dis Sci. 2013;58:724–33.
32. Zhang W, Gao Y, Li P, et al. VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. Cell Res. 2014;24(3):331–43.